Genentech Likely To Wait For Survival Data For U.S. Filing Of Avastin In Ovarian Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Avastin proves progression-free survival benefit for tough-to-treat patients in AURELIA, the drug’s fourth positive Phase III ovarian cancer study. Genentech says it plans to “engage” with FDA regarding a filing, but acknowledges that the agency may want more data, possibly showing an overall survival benefit.